Chief Executive Officer at UNITY Biotechnology.
Anirvan joined UNITY as CEO in March 2020. Prior to joining UNITY, he served as senior vice president and head of research and early development at Biogen. During his tenure at Biogen, Anirvan led a team of 350 scientists and clinicians responsible for preclinical, and clinical Phase 1 and Phase 2 studies in all of Biogen’s disease areas and led a marked expansion of its early clinical portfolio. Between 2017 and 2020, ten assets advanced from Research to Development and several reported positive proof of concept studies and are now in pivotal registration-enabling clinical trials. Anirvan was also involved in expanding the portfolio through key partnerships, including acquisition of early stage assets in Alzheimer’s Disease, Schizophrenia, and Ophthalmology, and several multi-asset platform collaborations.
Visit website: http://ghoshlab.org/
See also: UNITY Biotechnology - Biotechnology company devoted to research of restoring human health
Anirvan Ghosh News
Unity's senolytic drug reports positive phase 1 data in eye disease patients
FierceBiotech - 06-Jul-2021
Begun phase 2 trial including patients with early stage of disease to test its safety and effectivenessRead more...
Super summary of 3rd Annual Longevity Therapeutics Summit
Lifespan.io (LEAF) - 16-Feb-2021
More and more companies making greater and greater progress - 2021 could be an exciting yearRead more...
Nature Biotechnology reviews the state of play of senolytics
Nature Biotechnology - 12-Nov-2020
In August, Unity announced that its lead drug candidate had failed to beat a placebo in reducing ...Read more...
Unity Biotechnology launches clinical trial of a new senolytic
Lifespan.io (LEAF) - 13-Oct-2020
A new approach to treat diabetic macular oedemaRead more...